Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Anthos Therapeutics, Inc.
With
Novartis Pharmaceuticals
Age
55–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female patients ≥ 55 years old
Patients with a history of atrial fibrillation (AF) or atrial flutter with planned indefinite anticoagulation
Patients with a CHA2DS2-VASc of ≥4 OR a CHA2DS2-VASc of ≥3 with at least 1 of the following:
1. Planned concomitant use of antiplatelet medication use (i.e., aspirin and/or P2Y12 inhibitor) for the duration of the trial
2. Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation
You may not be if
History of hypersensitivity to any of the study drugs (including rivaroxaban) or its excipients, to drugs of similar chemical classes, or any contraindication listed in the label for rivaroxaban
Patients with an intracranial or intraocular bleed within the 3 months prior to screening
Clinically significant mitral stenosis (valve area \<1.5 cm2)
Mechanical heart valve or other indication for anticoagulation therapy other than atrial fibrillation (e.g., venous thromboembolism)
Known presence of an atrial myxoma or left ventricular thrombus
History of left atrial appendage closure or removal
Active endocarditis
Clareo Health | Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
